{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:01:42Z","timestamp":1791464502575,"version":"4.3.4"},"reference-count":90,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"General University Hospital in Prague","award":["MH CZ-DRO-VFN64165"],"award-info":[{"award-number":["MH CZ-DRO-VFN64165"]}]},{"name":"MorphoSys AG","award":["MH CZ-DRO-VFN64165"],"award-info":[{"award-number":["MH CZ-DRO-VFN64165"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Immunoglobulin A nephropathy (IgAN) is a rare autoimmune disorder and the leading cause of biopsy-reported glomerulonephritis (GN) worldwide. Disease progression is driven by the formation and deposition of immune complexes composed of galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1 autoantibodies (anti-Gd-IgA1 antibodies) in the glomeruli, where they trigger complement-mediated inflammation that can result in loss of kidney function and end-stage kidney disease (ESKD). With the risk of progression and limited treatment options, there is an unmet need for therapies that address the formation of pathogenic Gd-IgA1 antibody and anti-Gd-IgA1 antibody-containing immune complexes. New therapeutic approaches target immunological aspects of IgAN, including complement-mediated inflammation and pathogenic antibody production by inhibiting activation or promoting depletion of B cells and CD38-positive plasma cells. This article will review therapies, both approved and in development, that support the depletion of Gd-IgA1-producing cells in IgAN and have the potential to modify the course of this disease. Ultimately, we propose here a novel therapeutic approach by depleting CD38-positive plasma cells, as the source of the autoimmunity, to treat patients with IgAN.<\/jats:p>","DOI":"10.3390\/jcm11102810","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T13:06:23Z","timestamp":1652706383000},"page":"2810","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies"],"prefix":"10.3390","volume":"11","author":[{"given":"Dita","family":"Maixnerova","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, General University Hospital, Charles University, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"El Mehdi","sequence":"additional","affiliation":[{"name":"MorphoSys, MorphoSys US Inc., Boston, MA 02210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-0689","authenticated-orcid":false,"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, General University Hospital, Charles University, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA Nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA Nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The Incidence of Primary Glomerulonephritis Worldwide: A Systematic Review of the Literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA Nephropathy: A Global Perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ki.2013.474","article-title":"Dialysis Frequency versus Dialysis Time, That Is the Question","volume":"85","author":"Hakim","year":"2014","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/ndt\/gfm022","article-title":"EBPG Guideline on Dialysis Strategies","volume":"22","author":"Tattersall","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2147\/PPA.S156356","article-title":"The Impact on Quality of Life of Dialysis Patients with Renal Insufficiency","volume":"12","author":"Dykowska","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical Epidemiology of Cardiovascular Disease in Chronic Renal Disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1159\/000355745","article-title":"Long-Term Survival of Patients with IgA Nephropathy after Dialysis Therapy","volume":"37","author":"Komatsu","year":"2013","journal-title":"Kidney Blood Press. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/TP.0000000000001093","article-title":"Recurrent IgA Nephropathy After Kidney Transplantation","volume":"100","author":"Wyld","year":"2016","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1093\/ndt\/gfq223","article-title":"Long-Term Outcome of Renal Transplantation in Patients with Idiopathic Membranous Glomerulonephritis (MN)","volume":"25","author":"Moroni","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"726215","DOI":"10.3389\/fimmu.2021.726215","article-title":"Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation","volume":"12","author":"Maixnerova","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fimmu.2016.00117","article-title":"The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy","volume":"7","author":"Knoppova","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(Hi)CD138(+) Subset in Human Bone Marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","article-title":"The Maintenance of Memory Plasma Cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","article-title":"Biomarkers for IgA Nephropathy on the Basis of Multi-Hit Pathogenesis","volume":"23","author":"Suzuki","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrneph.2012.58","article-title":"Pathogenesis of IgA Nephropathy","volume":"8","author":"Lai","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The Pathophysiology of IgA Nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Maixnerova, D., Ling, C., Hall, S., Reily, C., Brown, R., Neprasova, M., Suchanek, M., Honsova, E., Zima, T., and Novak, J. (2019). Galactose-Deficient IgA1 and the Corresponding IgG Autoantibodies Predict IgA Nephropathy Progression. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219947"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12013-013-9741-2","article-title":"IgA Nephropathy Factors That Predict and Accelerate Progression to End-Stage Renal Disease","volume":"68","author":"Huang","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Maixnerova, D., and Tesar, V. (2020). Emerging Modes of Treatment of IgA Nephropathy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239064"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","article-title":"Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study","volume":"6","author":"Bagchi","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_26","unstructured":"Travere Therapeutics, Inc. (2022, March 28). A Randomized, Multicenter, Double-Blind, Parallel-Group, Active-Control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy, Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual Inhibition of Renin-Angiotensin-Aldosterone System and Endothelin-1 in Treatment of Chronic Kidney Disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am. J. Physio.l Regul. Integr. Comp. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A Pre-Specified Analysis of the DAPA-CKD Trial Demonstrates the Effects of Dapagliflozin on Major Adverse Kidney Events in Patients with IgA Nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_29","unstructured":"Morphosys Farxiga (Dapagliflozin) (2022, March 28). [Package Insert]. Available online: https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/0be9cb1b-3b33-41c7-bfc2-04c9f718e442\/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After Ten Years of Follow-up, No Difference between Supportive Care plus Immunosuppression and Supportive Care Alone in IgA Nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"ref_32","unstructured":"Calliditas Therapeutics Tarpeyo (Budesomide) (2022, March 28). [Package Insert]. Available online: https:\/\/www.tarpeyo.com\/prescribinginformation.pdf."},{"key":"ref_33","unstructured":"FDA (2021). FDA Approves First Drug to Decrease Urine Protein in IgA Nephropathy, a Rare Kidney Disease."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2215\/CJN.04370418","article-title":"Insights into the Role of Mucosal Immunity in IgA Nephropathy","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11462","DOI":"10.7150\/thno.49778","article-title":"Perspectives on How Mucosal Immune Responses, Infections and Gut Microbiome Shape IgA Nephropathy and Future Therapies","volume":"10","author":"He","year":"2020","journal-title":"Theranostics"},{"key":"ref_37","first-page":"186","article-title":"T Lymphocytes in IgA Nephropathy","volume":"20","author":"Tang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3960\/jslrt.52.161","article-title":"IgA Production and Tonsillar Focal Infection in IgA Nephropathy","volume":"52","author":"Meng","year":"2012","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fmed.2020.00092","article-title":"The Role of Immune Modulation in Pathogenesis of IgA Nephropathy","volume":"7","author":"Chang","year":"2020","journal-title":"Front. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/sji.12128","article-title":"Functional Implications of Regulatory B Cells in Human IgA Nephropathy","volume":"79","author":"Wang","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","article-title":"TLR9 and BAFF: Their Expression in Patients with IgA Nephropathy","volume":"10","author":"Li","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10157-019-01700-1","article-title":"New Strategies and Perspectives on Managing IgA Nephropathy","volume":"23","author":"Selvaskandan","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/ndt\/gfy064","article-title":"Defective Gene Expression of the Membrane Complement Inhibitor CD46 in Patients with Progressive Immunoglobulin A Nephropathy","volume":"34","author":"Coppo","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0272-6386(88)80022-2","article-title":"The Immunohistology of IgA Nephropathy","volume":"12","author":"Jennette","year":"1988","journal-title":"Am. J. Kidney Dis."},{"key":"ref_48","unstructured":"Barratt, J. (2022, March 15). Interim Analysis of a Phase 2 Dose Ranging Study to Investigate the Effect and Safety of Iptacopan in Primary IGA Nephropathy. Available online: https:\/\/era-edta.conference2web.com\/#!resources\/interim-analysis-of-a-phase-2-dose-ranging-study-to-investigate-the-efficacy-and-safety-of-iptacopan-in-primary-iga-nephropathy-20ec3f83-fd34-441e-8745-44587bda74da."},{"key":"ref_49","unstructured":"(2022, March 15). Novartis Announces Iptacopan Met Phase II Study Primary Endpoint in Rare Kidney Disease IgA Nephropathy (IgAN). Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-iptacopan-met-phase-ii-study-primary-endpoint-rare-kidney-disease-iga-nephropathy-igan."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.ekir.2022.01.577","article-title":"Pos-546 Efficacy and Safety of Iptacopan in Iga Nephropathy: Results of a Randomized Double-Blind Placebo-Controlled Phase 2 Study at 6 Months","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lafayette, R.A., Carroll, K., and Barratt, J. (2021, January 4\u20137). Long-Term Phase 2 Efficacy of the MASP-2 Inhibitor Narsoplimab for Treatment of Severe IgA Nephropathy. Proceedings of the ASN Kidney Week 2021, San Diego, CA, USA.","DOI":"10.1016\/j.ekir.2022.01.119"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_53","unstructured":"Wire, B. (2022, March 15). Omeros Announces Results From Nearly Three-Year Follow-Up of Patients in Phase 2 IgA Nephropathy Trial. Available online: https:\/\/www.benzinga.com\/node\/23920855."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-Molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"152001","DOI":"10.1016\/j.imbio.2020.152001","article-title":"Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab","volume":"225","author":"Rambaldi","year":"2020","journal-title":"Immunobiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity","volume":"11","author":"Wilson","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e000499","DOI":"10.1136\/lupus-2021-000499","article-title":"Reductions in Circulating B Cell Subsets and Immunoglobulin G Levels with Long-Term Belimumab Treatment in Patients with SLE","volume":"9","author":"Struemper","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary Membranous Nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_61","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) (2022, March 28). NCT03949855: Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI), Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Barratt, J., Hour, B.T., Schwartz, B.S., Sorensen, B., Roy, S.E., Stromatt, C.L., MacDonald, M., Endsley, A.N., Lo, J., and Glicklich, A. (2021, January 4\u20137). Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1\/2 Trial. Proceedings of the ASN Kidney Week 2021, San Diego, CA, USA.","DOI":"10.1681\/ASN.20213210S1509b"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Barratt, J., Tumlin, J.A., Suzuki, Y., Kao, A., Aydemir, A., Zima, Y., and Appel, G.B. (2020, January 20\u201325). 24-Week Interim Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Proceedings of the ASN Kidney Week 2020, Denver, CO, USA.","DOI":"10.1681\/ASN.20203110S154b"},{"key":"ref_64","unstructured":"Vera Therapeutics, Inc. (2022, March 28). NCT04716231: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IGAN), Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lv, J., Liu, L.-J., Hao, C.-M., Li, G., Fu, P., Xing, G., Zheng, H., Chen, N., Caili, W., and Luo, P. (2021, January 4\u20137). A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Telitacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Proceedings of the ASN Kidney Week 2021, San Diego, CA, USA.","DOI":"10.1681\/ASN.20213210S1B10a"},{"key":"ref_66","unstructured":"RemeGen Co. Ltd. (2022, March 28). NCT04905212: A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy, Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_68","unstructured":"(2022, March 22). Visterra NCT04287985: Safety and Efficacy Study of VIS649 for IgA Nephropathy\u2014Full Text View\u2014ClinicalTrials.Gov, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04287985?term=nct04287985&draw=2&rank=1."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why Target the Gut to Treat IgA Nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/mi.2007.6","article-title":"The Immune Geography of IgA Induction and Function","volume":"1","author":"Macpherson","year":"2008","journal-title":"Mucosal Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.kint.2021.04.026","article-title":"Nasal-Associated Lymphoid Tissue Is the Major Induction Site for Nephritogenic IgA in Murine IgA Nephropathy","volume":"100","author":"Kano","year":"2021","journal-title":"Kidney Int."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nakata, J., Suzuki, Y., Suzuki, H., Sato, D., Kano, T., Yanagawa, H., Matsuzaki, K., Horikoshi, S., Novak, J., and Tomino, Y. (2014). Changes in Nephritogenic Serum Galactose-Deficient IgA1 in IgA Nephropathy Following Tonsillectomy and Steroid Therapy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089707"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13075-018-1718-5","article-title":"Increase of Circulating Memory B Cells after Glucocorticoid-Induced Remission Identifies Patients at Risk of IgG4-Related Disease Relapse","volume":"20","author":"Lanzillotta","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2017.05.021","article-title":"Mucosal Corticosteroid Therapy of IgA Nephropathy","volume":"92","author":"Floege","year":"2017","journal-title":"Kidney Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/ndt\/gfz249","article-title":"Systemic Corticosteroids and Mucosal-Associated Lymphoid Tissue-Targeted Therapy in Immunoglobulin A Nephropathy: Insight from the NEFIGAN Study","volume":"35","author":"Coppo","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial","volume":"389","author":"Barratt","year":"2017","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1016\/j.ekir.2021.03.868","article-title":"POS-830 NEFECON for the Treatment of IgA Nephropathy in Patients at Risk of Progressing to End-Stage Renal Disease: The NEFIgArd Phase 3 Trial Results","volume":"6","author":"Barratt","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_78","unstructured":"Calliditas Therapeutics AB (2022, March 28). NCT03643965: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd), Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for Reduction of Proteinuria in IgA Nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_80","unstructured":"MorphoSys AG (2022, March 28). NCT05065970: A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy, Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.V126.23.3015.3015","article-title":"MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds","volume":"126","author":"Boxhammer","year":"2015","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1-2a Trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood.V120.21.4018.4018","article-title":"The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo","volume":"120","author":"Endell","year":"2012","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.4049\/jimmunol.180.4.2294","article-title":"Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats","volume":"180","author":"Tawara","year":"2008","journal-title":"J. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rovin, B.H., Adler, S.G., Hoxha, E., Sprangers, B., Stahl, R., Wetzels, J.F., Schwamb, B., Boxhammer, R., Nguyen, Q., and Haertle, S. (2021, January 4\u20137). Felzartamab in Patients with Anti-Phospholipase A2 Receptor Autoantibody Positive (Anti-PLA2R+) Membranous Nephropathy (MN): Interim Results from the M-PLACE Study. Proceedings of the ASN Kidney Week 2021, San Diego, CA, USA.","DOI":"10.1681\/ASN.20213210S1513c"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rovin, B., Adler, S.G., Hoxha, E., Sprangers, B., Stahl, R., Wetzels, J.F., Jauch-Lembach, J., Griese, J., Boxhammer, R., and Xu, L. (2022, January 6\u201310). Felzartamab in Patients with Anti-Phospholipase A2 Receptor Autoantibody-Positive (Anti-PLA2R Ab+) Membranous Nephropathy (MN): Preliminary Results from the M-PLACE Study. Proceedings of the National Kidney Foundation Spring Clinical Meetings, Boston, MA, USA.","DOI":"10.1681\/ASN.20213210S1513c"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood.V128.22.1152.1152","article-title":"A Phase I\/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Raab","year":"2016","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000491439","article-title":"Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications","volume":"10","author":"Heesterbeek","year":"2018","journal-title":"J. Innate Immun."},{"key":"ref_90","unstructured":"Alberts, B. (2002). Molecular Biology of the Cell, Garland Science. [4th ed.]."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2810\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:11:28Z","timestamp":1760137888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":90,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jcm11102810"],"URL":"https:\/\/doi.org\/10.3390\/jcm11102810","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}